Source: Emyria
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Emyria (EMD) receives further positive MDMA analogue screening results
  • The company has been progressing its ecstasy analogue development program, which is being run in partnership with the University of Western Australia
  • The results bring the total count of successfully screened MDMA analogues to date to 83 out of 85
  • Additional preclinical screenings are now being planned with a leading research organisation who will perform assays to evaluate the solubility, partition coefficients and metabolic stability of each compound
  • Emyria climbs 6 per cent, trading at 26.5 cents

Emyria (EMD) has received further positive MDMA analogue screening results.

The company has been progressing its ecstasy analogue development program, which is being run in partnership with the University of Western Australia.  

16 out of 17 compounds sent from the second batch of analogues passed screening with Eurofins at the test concentrations. This means these compounds showed no evidence of interactions with one or more of the enzymes or cell receptors that can be associated with unwanted clinical side effects.

These results bring the total count of successfully screened MDMA analogues to date to 83 out of 85.

Additional preclinical screenings are now being planned with a leading research organisation, who will perform a number of assays to evaluate the solubility, partition coefficients and metabolic stability of each compound.

The company said these assays can help to predict absorption and brain uptake rates and help identify compounds that are similar to MDMA in potency, but with faster onset and shorter half-lives, which may be more suitable for clinical applications.

“We are now planning pivotal preclinical studies to help identify which of these compounds may have the potency of common MDMA but with enhanced safety and shorter acting times and half-lives,” Managing Director Michael Winlo said.

“We anticipate this screening program will help identify compounds with the potential to become registered treatments for other neuropsychiatric conditions,” Dr Winlo added.

Emyria climbed 6 per cent, trading at 26.5 cents at 3:59 pm AEST.  

EMD by the numbers
More From The Market Herald
Little Green Pharma (ASX:LGP) - CEO, Fleta Solomon

" Little Green Pharma (ASX:LGP) enters take-or-pay contract with Four 20 Pharma

Little Green Pharma (ASX:LGP) has entered a 2.5-year take-or-pay contract with Four 20 Pharma for the…
Reckon (ASX:RKN) - CEO, Sam Allert

" Reckon (ASX:RKN) to sell Accountants Practice Management Group for $100m

Software company Reckon (ASX:RKN) to sell its Accountants Practice Management Group to Access Group for $100…

" Discovery Alaska (ASX:DAF) finds first-ever lithium at Coal Creek

Discovery Alaska (ASX:DAF) has discovered lithium at the Coal Creek prospect within its Chulitna project in…

" Talon Energy (ASX:TPD) progresses WA and Mongolia gas projects

Over the past three months, Talon Energy (ASX:TPD) has been focusing on its Walyering conventional gas…